Gilead Sciences Inc. will charge a lower price of $390 a dose of remdesivir to some U.S. government agencies that directly purchase pharmaceuticals, such as the Department of Veterans Affairs. "Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient on Private Insurance, " at 7 a.m. and 10:41 a.m., incorrectly said the lower price would be extended to government health programs such as Medicare.

 

(END) Dow Jones Newswires

June 29, 2020 13:19 ET (17:19 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Gilead Sciences Charts.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Gilead Sciences Charts.